Mr 2.24.14
Upcoming SlideShare
Loading in...5

Like this? Share it with your network

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads


Total Views
On Slideshare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. Immune thrombocytopenic purpura SAMREEN RAZA, MD PGY-3
  • 2. Immune thrombocytopenic purpura  There are only two criteria required in order to make this diagnosis:  1. Isolated thrombocytopenia is present – rest of blood count is normal including peripheral smear  2. Clinically apparent associated conditions absent (eg, systemic lupus erythematosus, antiphospholipid syndrome, chronic lymphocytic leukemia)  Patients with these associated conditions are described as having "secondary immune thrombocytopenia  Herbal supplements and drugs not considered part of etiology
  • 3. Pathogenesis  Related to a combination of increased platelet destruction along with inhibition of megakaryocyte platelet production via the production of specific IgG autoantibodies by the patient's B cells, most often directed against platelet membrane glycoproteins such as GPIIb/IIIa  Inciting events - etiology of ITP is unclear, but is thought to include genetic as well as acquired factors  Some cases of ITP are associated with a preceding viral infection:  Resulting anti-viral antibodies cross-react with platelet glycoproteins  Infection with HIV, HCV, CMV and VZV may be associated with such antibodies therefore cause secondary ITP.  Alterations in the immune response might induce loss of peripheral tolerance and promote the development of self-reactive antibodies  Abnormalities in the immune system may predispose to the development of ITP
  • 4. Incidence  Incidence greater in children than adults  Danish study from 1973 to 1995 estimated annual incidence of ITP among adults to be 22 per million per year, using a platelet count cutoff of 50,000/microL  Incidence rose during the study period due to increased recognition of asymptomatic patients  Among adults with ITP, approx 70% are women and 72% of these women are less than 40 years of age  The Denmark survey reported a sex difference in the incidence of ITP only for those <60 years of age  Generalizability?
  • 5. Physical examination features  Mucocutaneous features related to thrombocytopenia and bleeding  Not visceral hematomas which are characteristic of coagulation disorders eg hemophilia  Petechiae, purpura, ecchymoses  Epistaxis, gingival bleeding, menorrhagia  Overt gastrointestinal bleeding and gross hematuria are rare  Intracranial hemorrhage – very rare  The clinical manifestations of thrombocytopenia vary with age  Patients may have more severe bleeding manifestations including GI bleeding or ICH due to comorbidities such as hypertension
  • 6. Diagnostic testing  Peripheral smear — Examination of the blood smear may provide evidence for other causes of thrombocytopenia eg presence of schistocytes  Examination of the peripheral blood smear is essential to exclude pseudothrombocytopenia due to the artifact of platelet agglutination induced by the standard blood count anticoagulant, EDTA  EDTA-dependent agglutinins are present in approximately 0.1% people in the general population  naturally occuring platelet antibody against normally concealed epitope on GpIIb/IIIa which becomes exposed by EDTA-induced dissociation of GpIIb/IIIa  You can make a presumptive diagnosis based on history, physical examination, CBC and examination of peripheral blood smear with isolated thrombocytopenia  H pylori infection – generally do not screen for this in patients with mild or moderate thrombocytopenia  Can do breath test or fecal antigen testing only in patients if ITP is chronic or refractory or if positive test would change management
  • 7. Other causes Beverages and herbal remedies that can cause thrombocytopenia include:  Quinine  Tonic water  Sulfonamides including sulfamethoxazole  Heparin
  • 8. Antiplatelet antibodies The American Society of Hematology ITP Practice Guidelines do not recommend antiplatelet antibody studies in patients thought to have ITP No evidence that antiplatelet antibody studies are important for diagnosis of ITP
  • 9. Differential diagnosis TTP/HUS DIC Gestational thrombocytopenia Drugs Infection Hypersplenism Myelodysplasia Congential thrombocytopenias
  • 10. Inherited platelet disorders  von Willebrand disease type 2B: with greater than expected bleeding for the degree of thrombocytopenia  Wiskott-Aldrich syndrome and its variant, X-linked thrombocytopenia, with small platelets and recurrent infections  Alport syndrome (hereditary nephritis) variants, with giant platelets, renal failure, and hearing loss  May-Hegglin anomaly, with giant platelets and Döhle bodies in granulocytes, and other manifestations of MYH9 gene mutations (the gene encoding the nonmuscle myosin heavy chain IIA)  Fanconi syndrome, with short stature, anemia, and neutropenia  Bernard-Soulier syndrome, with giant platelets and greater than expected bleeding for the degree of thrombocytopenia  Thrombocytopenia with absent radius (TAR) syndrome, with skeletal abnormalities  Gray platelet syndrome, with giant platelets lacking alpha granules and predisposition to myelofibrosis
  • 11. Treatment  Major bleeding is rare in patients with ITP - platelet count <10,000  Goal for treatment is to provide a safe platelet count to prevent major bleeding rather than returning the platelet count to normal  Adults with severe thrombocytopenia (< 30,000) at the time of diagnosis are almost always treated even if they are asymptomatic or have only minor bleeding symptoms, course of the disease and future risk is unknown  Pts with severe chronic thrombocytopenia who have only partial response to treatment is uncertain – individual management decisions
  • 12. Treatment  Glucocorticoids  The goal of initial glucocorticoid treatment is not to "cure" the ITP, but to support the platelet count in a safe range with minimal and tolerable side effects until a spontaneous remission occurs or until more definitive therapy established  Prednisone – standard practice – oral 1mg/kg single daily dose, most respond within 2 weeks, can taper once responds  High-dose dexamethasone – role of this is being actively investigated  Dosing of 40mg per day with PO or IV for 4-8 days  Follow response to treatment  IVIG: temporarily supports platelet count  Dose: 1g/kg/day for 1 or 2 days  Can use for life-threatening bleeding
  • 13. References Immune thrombocytopenic purpura. NEJM 2002;346(13):995 Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3 UTDOL